Wegovy’s CV Risk-Reduction Approval: Why It Changed Obesity Care

Topic: Regulatory update

In March 2024, the FDA granted a new indication for Wegovy (Semaglutide): reducing the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight.

This might sound like dry regulatory news, but it is a massive shift in how the medical system views weight.

The Significance

Before this, Semaglutide was classified strictly as a “weight management” drug.

• Insurance: Many insurance providers (and public health systems) deny coverage for weight loss drugs, viewing them as “cosmetic” or “lifestyle” choices.
• Stigma: Patients were often told to “just try harder” rather than being offered medical support.

The New Reality

Now, Wegovy is a Cardiovascular Drug.

• The Proof: This approval was based on the SELECT trial data, showing a 20% reduction in major adverse heart events.
• The Access: It becomes much harder for insurers to deny coverage for a drug that is proven to prevent heart attacks. It moves obesity treatment from the “optional” bucket to the “medically necessary” bucket.

What This Means for Women

Women with high BMI and metabolic risk factors (Lipids, BP, Pre-diabetes) often face barriers to care. This approval arms your doctor with a stronger justification to prescribe effective therapy. It confirms that treating your weight is treating your heart.